Skip to content

Karoline Kielbassa

Lymphoma and Myeloma Center Amsterdam, LYMMCARE, Department of Experimental Immunology, Amsterdam UMC location AMC, Amsterdam, Netherlands.

Since January 2019, I am pursuing a PhD program under supervision of Eric Eldering, Arnon P. Kater and Taco Kuijpers at the Amsterdam UMC.

I am studying the selective effects of BTK and novel inhibitors of Bcl-2 family members in both healthy and malignant post-B-cell activation pathways of plasma cell differentiation and survival.

Besides studying the effects in chronic lymphocytic leukemia (CLL), we are also interested whether those inhibitors of Bcl-2 family members can be applied in autoimmune diseases such as systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).

Recent Publication:

Changes in Bcl-2 members in response to ibrutinib or venetoclax uncover functional hierarchy in determining resistance to venetoclax in CLL.  Haselager MV, Kielbassa K, Ter Burg J, Bax DJC, Fernandes SM, Borst J, Tam C, Forconi F, Chiodin G, Brown JR, Dubois J, Kater AP, Eldering E. Blood. 2020 Jun 30

Member of work package 2 and 5.

Back To Top